AbCellera Biologics (ABCL) Accounts Payables (2020 - 2025)
Historic Accounts Payables for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $53.1 million.
- AbCellera Biologics' Accounts Payables fell 121.99% to $53.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.1 million, marking a year-over-year decrease of 121.99%. This contributed to the annual value of $55.0 million for FY2024, which is 1093.99% up from last year.
- According to the latest figures from Q3 2025, AbCellera Biologics' Accounts Payables is $53.1 million, which was down 121.99% from $50.1 million recorded in Q2 2025.
- In the past 5 years, AbCellera Biologics' Accounts Payables ranged from a high of $55.0 million in Q4 2024 and a low of $13.3 million during Q1 2021
- Its 5-year average for Accounts Payables is $38.5 million, with a median of $42.9 million in 2024.
- In the last 5 years, AbCellera Biologics' Accounts Payables soared by 11482.16% in 2023 and then crashed by 1611.41% in 2024.
- Quarter analysis of 5 years shows AbCellera Biologics' Accounts Payables stood at $32.0 million in 2021, then surged by 63.97% to $52.5 million in 2022, then fell by 5.56% to $49.6 million in 2023, then increased by 10.94% to $55.0 million in 2024, then decreased by 3.43% to $53.1 million in 2025.
- Its Accounts Payables stands at $53.1 million for Q3 2025, versus $50.1 million for Q2 2025 and $47.8 million for Q1 2025.